Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.
Fiche publication
Date publication
janvier 2019
Journal
European urology oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain
Tous les auteurs :
Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC,
Lien Pubmed
Résumé
Patients with residual muscle-invasive urinary tract cancer after neoadjuvant chemotherapy (NAC) have a high risk of recurrence.
Mots clés
Adjuvant chemotherapy, Muscle-invasive bladder cancer, Muscle-invasive urinary tract cancer, Neoadjuvant chemotherapy, Residual disease, Risk of relapse, Time to recurrence
Référence
Eur Urol Oncol. 2019 Jan 30;: